Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Benralizumab Regulates Atopic Dermatitis Through Effects on Eosinophils, Basophils and Innate Lymphoid Type 2 Cells.

NCT03563066 is registered in ClinicalTrials.gov with McMaster University as lead sponsor.

NCT NCT03563066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03563066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Benralizumab Regulates Atopic Dermatitis Through Effects on Eosinophils, Basophils and Innate Lymphoid Type 2 Cells.
Lead sponsor
McMaster University
Phase
Phase 2
Overall status
Completed
Start date
September 4, 2018
Completion date
September 28, 2021
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dermatitis, dermatitis, atopic, eczema, genetic diseases, inborn, hypersensitivity, hypersensitivity, immediate, immune system diseases, skin diseases, skin diseases, eczematous, skin diseases, genetic